Stryker Corporation(SYK)Earnings, Financials & Key RatiosStryker Corporation (SYK) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the current 22.18 forward P/E ratio appears difficult to justify given the recent deceleration in revenue growth to 2.6% and the persistent pressure on operating margins, which fell to 15.5% in 2026Q1.
Stryker Corporation (SYK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Stryker Corporation (SYK) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $2.60vs $2.98-12.8% | $6.0Bvs $6.3B-5.0% |
| Q1 2026 | Jan 29, 2026 | $4.47vs $4.40+1.6% | $7.2Bvs $7.1B+0.7% |
| Q4 2025 | Oct 30, 2025 | $3.19vs $3.13+1.9% | $6.1Bvs $6.0B+0.2% |
| Q3 2025 | Jul 31, 2025 | $3.13vs $3.07+2.0% | $6.0Bvs $5.9B+1.4% |
Recent stock market news and headlines for Stryker Corporation (SYK)
Stryker (SYK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
PORTAGE, Mich., June 24, 2026 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, today announced a new partnership with Major Champion and globally recognized golfer Shane Lowry at the Travelers Championship in Cromwell, Connecticut, naming him a sponsored brand ambassador for its Joint Replacement division.
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two companies is the best option for those looking for undervalued stocks?
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Vistra Corp. (NYSE:VST), adding it “went too high. It's come back down.
Key metrics vs top competitors for Stryker Corporation (SYK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $313.38 | $120.14B | 37.31 | 11.16% | 12.92% | 15.08% | 1.07% | |
| $89.76 | $17.58B | 25.28 | 7.2% | 9.05% | 5.77% | — | |
| $44.60 | $66.29B | 22.99 | 19.87% | 17.23% | 14.67% | — | |
| $95.18 | $54.8B | 52.01 | 11.55% | 17.34% | 10.54% | — | |
| $155.54 | $56.35B | 26.68 | 8.23% | 5.33% | 4.54% | — | |
| $83.06 | $106.64B | 22.27 | 8.43% | 13.2% | 9.78% | — |
Stryker Corporation (SYK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Stryker Corporation (SYK) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 20, 2026·SEC
May 8, 2026·SEC
Apr 30, 2026·SEC
Get notified when SYK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Stryker Corporation (SYK) stock FAQ — growth, dividends, profitability & financials explained
Stryker Corporation (SYK) reported $25.27B in revenue for fiscal year 2025. This represents a 2677% increase from $910.1M in 1996.
Stryker Corporation (SYK) grew revenue by 11.2% over the past year. This is steady growth.
Yes, Stryker Corporation (SYK) is profitable, generating $3.34B in net income for fiscal year 2025 (12.9% net margin).
Yes, Stryker Corporation (SYK) pays a dividend with a yield of 1.07%. This makes it attractive for income-focused investors.
Stryker Corporation (SYK) has a return on equity (ROE) of 15.1%. This is reasonable for most industries.
Stryker Corporation (SYK) generated $4.57B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
